Clofazimine (Zhang 2024)
Source:vignettes/articles/Zhang_2024_clofazimine.Rmd
Zhang_2024_clofazimine.RmdModel and source
- Citation: Zhang CX, Conrad TM, Hermann D, Gordon MA, Houpt E, Iroh Tam PY, Jere KC, Nedi W, Operario DJ, Phulusa J, Quinnan GV Jr, Sawyer LA, Barrett LK, Thole H, Toto N, Van Voorhis WC, Arnold SLM. Clofazimine pharmacokinetics in HIV-infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics. CPT Pharmacometrics Syst Pharmacol. 2024;13(3):410-423. doi:10.1002/psp4.13092
- Description: Two-compartment population PK model for oral clofazimine in HIV-infected adults with and without cryptosporidiosis-associated diarrhea: first-order absorption with a lag time, linear elimination, relative bioavailability fixed at 1 in participants without diarrhea and reduced by the participant’s overall maximum diarrhea grade over the study (grade 1 and grade 2 shifts on log F), inter-individual variability on ka, V/F, Q/F and F, and inter-occasion (per study day) variability on F.
- Article: https://doi.org/10.1002/psp4.13092 (open access, PMC10941540)
- Supplement: Appendix S1 (Figures S1-S4, Tables S1-S2) at the article page
Clofazimine was studied as a treatment for cryptosporidiosis in a phase IIa trial (NCT03341767) in HIV-infected adults in Blantyre, Malawi. Zhang et al. used the trial’s pharmacokinetic substudy to ask how diarrhea changes the absorption of an orally administered drug. The answer was large: the participant’s highest diarrhea grade over the five dosing days was the only covariate retained, and it lowered the relative bioavailability about 6-fold (grade 1, mild) and 22-fold (grade 2, severe).
Population
The model was fitted in Phoenix NLME (FOCE-ELS) to 428 plasma concentrations from the 23 participants who received clofazimine (Table 2):
- Part A (n = 12): HIV-infected, Cryptosporidium-positive by qPCR, with at least 14 days of diarrhea at enrolment. Median age 40.5 years (range 30-51), median weight 45.45 kg (36.6-52), 4 women; median CD4 count 23 cells/uL and median HIV viral load about 140,000 copies/mL. Only 9 of the 12 had diarrhea during the dosing period.
- Part B (n = 11): HIV-infected, without cryptosporidiosis or diarrhea, matched to Part A on age, sex and weight. Median age 43 years (31-64), median weight 47 kg (41-53), 4 women; median CD4 count 419 cells/uL.
Overall maximum diarrhea grade over the study was 0 in 14 participants, 1 in 8 and 2 in one (all grade 1 and 2 participants were in Part A). Clofazimine was given orally with food at about 5 a.m., 11 a.m. and 6 p.m. for 5 days: 50 mg per dose below 50 kg body weight (20 participants) and 100 mg at or above 50 kg (3 participants).
The same information is available programmatically via
readModelDb("Zhang_2024_clofazimine")()$population.
Source trace
Every ini() value carries an in-file comment pointing to
its source in
inst/modeldb/specificDrugs/Zhang_2024_clofazimine.R. The
table below collects them.
| Equation / parameter | Value | Source location |
|---|---|---|
lka (ka) |
log(0.625 1/h) | Table 3, final model |
ltlag (Tlag) |
log(1.83 h) | Table 3, final model |
lfdepot (F, diarrhea-free) |
fixed(log(1)) | Table 3 (‘1 (fixed)’); Methods, structural model |
lcl (CL/F) |
log(3.71 L/h) | Table 3, final model |
lvc (V/F) |
log(473 L) | Table 3, final model |
lq (Q/F) |
log(18.2 L/h) | Table 3, final model |
lvp (V2/F) |
log(3434 L) | Table 3, final model |
e_diarrhea_max_grade_1_fdepot |
-1.80 | Table 3 ‘Overall max diarrhea grade = 1’; Results (Frel 0.165) |
e_diarrhea_max_grade_2_fdepot |
-3.08 | Table 3 ‘Overall max diarrhea grade = 2’; Results (Frel 0.0460) |
etalka |
149% CV -> 1.169 | Table 3 ‘IIV on ka’ |
etalvc |
3.46% CV -> 0.00120 | Table 3 ‘IIV on V/F’ |
etalq |
45.0% CV -> 0.184 | Table 3 ‘IIV on Q/F’ |
etalfdepot |
37.5% CV -> 0.132 | Table 3 ‘IIV on F’ |
etaiov_fdepot_1 … _5
|
36.8% CV -> 0.127 | Table 3 ‘Interoccasion variability on F’ |
addSd |
0.00268 mg/L | Table 3 ‘sigma’ |
propSd |
fixed(0) | Equation 1 has a proportional term; no value reported |
| Two-compartment model with lag and first-order absorption | n/a | Results, Structural PK model; Table S1 model 5 |
F = 1 x exp(eta_F + theta1 (grade = 1) + theta2 (grade = 2)) |
n/a | Equation 6 |
Par_i = theta_pop x exp(eta_i) |
n/a | Equation 2 |
Cobs = Cpred + Cpred x eps1 + eps2 |
n/a | Equation 1 |
Virtual cohort
The individual data are not public. The virtual cohort reproduces the
study design of Figure 1b: one arm per overall maximum diarrhea grade,
50 mg three times daily for 5 days, with the day of each dose carried as
the occasion (OCC) for the inter-occasion variability on F.
Time zero is the first dose at about 5 a.m. on day 1, so the daily doses
fall at 0, 6 and 13 h after the day’s first dose.
The PK samples of Figure 1b are flagged so the NCA can use the trial’s own sampling times: day 1 pre-dose, 2, 3 and 4 h after the first dose and before the second and third doses; before every dose on days 2, 3 and 5; 2, 3 and 4 h after the first dose on day 5; and one sample on the morning of day 6 (120 h). A 1-h grid is added for the plots.
dose_mg <- 50
dose_times <- as.vector(outer(c(0, 6, 13), 24 * (0:4), "+"))
sample_times <- sort(unique(c(
0, 2, 3, 4, 6, 13, # day 1
24, 30, 37, 48, 54, 61, # days 2-3, pre-dose
96, 98, 99, 100, 102, 109, # day 5
120 # day 6
)))
grid_times <- sort(unique(c(seq(0, 144, by = 1), sample_times)))
grades <- tibble(
grade = factor(c("Grade 0", "Grade 1", "Grade 2")),
DIARRHEA_MAX_GRADE_1 = c(0L, 1L, 0L),
DIARRHEA_MAX_GRADE_2 = c(0L, 0L, 1L)
)
# One arm per grade; `id_offset` keeps subject IDs disjoint across arms.
make_cohort <- function(n, arm, obs_times, id_offset = 0L) {
ids <- id_offset + seq_len(n)
doses <- tidyr::expand_grid(id = ids, time = dose_times) |>
mutate(evid = 1L, amt = dose_mg, cmt = "depot")
obs <- tidyr::expand_grid(id = ids, time = obs_times) |>
mutate(evid = 0L, amt = 0, cmt = "central")
bind_rows(doses, obs) |>
mutate(
# Occasion = study day (visit) of the record; F is evaluated on the dose
# records, which all fall on days 1-5.
OCC = pmin(floor(time / 24) + 1, 8),
grade = arm$grade,
DIARRHEA_MAX_GRADE_1 = arm$DIARRHEA_MAX_GRADE_1,
DIARRHEA_MAX_GRADE_2 = arm$DIARRHEA_MAX_GRADE_2
) |>
arrange(id, time, desc(evid))
}
n_per_arm <- 200L
events <- bind_rows(lapply(seq_len(nrow(grades)), function(i) {
make_cohort(n_per_arm, grades[i, ], grid_times,
id_offset = (i - 1L) * n_per_arm
)
}))
stopifnot(!anyDuplicated(events[, c("id", "time", "evid")]))Simulation
mod <- readModelDb("Zhang_2024_clofazimine")
rxode2::rxSetSeed(20240105)
sim <- rxode2::rxSolve(mod, events = events, keep = "grade") |>
as.data.frame() |>
mutate(Cc_ng = 1000 * Cc) # mg/L -> ng/mL
#> ℹ parameter labels from comments will be replaced by 'label()'
#> Warning: some etas defaulted to non-mu referenced, possible parsing error: etaiov_fdepot_1, etaiov_fdepot_2, etaiov_fdepot_3, etaiov_fdepot_4, etaiov_fdepot_5
#> as a work-around try putting the mu-referenced expression on a simple lineTypical-value profiles (all random effects set to zero), one subject per grade, run through the two follow-up visits (19-24 and 41-55 days after the last dose):
mod_typical <- mod |> rxode2::zeroRe()
#> ℹ parameter labels from comments will be replaced by 'label()'
#> Warning: some etas defaulted to non-mu referenced, possible parsing error: etaiov_fdepot_1, etaiov_fdepot_2, etaiov_fdepot_3, etaiov_fdepot_4, etaiov_fdepot_5
#> as a work-around try putting the mu-referenced expression on a simple line
#> Warning: some etas defaulted to non-mu referenced, possible parsing error: etaiov_fdepot_1, etaiov_fdepot_2, etaiov_fdepot_3, etaiov_fdepot_4, etaiov_fdepot_5
#> as a work-around try putting the mu-referenced expression on a simple line
long_times <- sort(unique(c(seq(0, 144, by = 0.5), seq(150, 1500, by = 6))))
events_typical <- bind_rows(lapply(seq_len(nrow(grades)), function(i) {
make_cohort(1L, grades[i, ], long_times, id_offset = i - 1L)
}))
sim_typical <- rxode2::rxSolve(mod_typical, events = events_typical, keep = "grade") |>
as.data.frame() |>
mutate(Cc_ng = 1000 * Cc)
#> ℹ omega/sigma items treated as zero: 'etalka', 'etalvc', 'etalq', 'etalfdepot', 'etaiov_fdepot_1', 'etaiov_fdepot_2', 'etaiov_fdepot_3', 'etaiov_fdepot_4', 'etaiov_fdepot_5'
#> Warning: multi-subject simulation without without 'omega'Replicate published figures
Concentration-time profiles by overall maximum diarrhea grade (Figure 4 and Figure S1)
Figure 4 plots the observed concentrations by overall maximum diarrhea grade, and Figure S1 the grade-stratified prediction-corrected VPCs. Below are the simulated median and 90% prediction interval for each grade over the first six days; the separation of roughly an order of magnitude between grades 0 and 1, and again between grades 1 and 2, is the feature Figure 4 shows.
vpc <- sim |>
filter(time > 0) |>
group_by(grade, time) |>
summarise(
q05 = quantile(Cc_ng, 0.05), q50 = median(Cc_ng), q95 = quantile(Cc_ng, 0.95),
.groups = "drop"
)
ggplot(vpc, aes(time / 24, q50, colour = grade, fill = grade)) +
geom_ribbon(aes(ymin = q05, ymax = q95), alpha = 0.2, colour = NA) +
geom_line() +
scale_y_log10() +
labs(
x = "Time since first dose (days)", y = "Clofazimine (ng/mL)",
colour = "Overall max\ndiarrhea grade", fill = "Overall max\ndiarrhea grade",
caption = "Replicates Figure 4 and Figure S1 of Zhang 2024 (50 mg t.i.d., 200 virtual participants per grade)."
) +
theme_bw()
#> Warning in scale_y_log10(): log-10 transformation introduced infinite values.
#> log-10 transformation introduced infinite values.
#> log-10 transformation introduced infinite values.
#> log-10 transformation introduced infinite values.
Whole-study typical profile (Figure 3a)
Figure 3a spans the follow-up visits. Clofazimine’s terminal half-life of about 35 days means concentrations at the final visit are still a sizeable fraction of the day-5 peak.
ggplot(filter(sim_typical, time > 0), aes(time / 24, Cc_ng, colour = grade)) +
geom_line() +
annotate("rect",
xmin = (109 + 19 * 24) / 24, xmax = (109 + 24 * 24) / 24,
ymin = 0, ymax = Inf, alpha = 0.1
) +
annotate("rect",
xmin = (109 + 41 * 24) / 24, xmax = (109 + 55 * 24) / 24,
ymin = 0, ymax = Inf, alpha = 0.1
) +
scale_y_log10() +
labs(
x = "Time since first dose (days)", y = "Clofazimine (ng/mL)",
colour = "Overall max\ndiarrhea grade",
caption = paste(
"Typical-value profiles; shaded bands are the follow-up visit windows.",
"Compare Figure 3a of Zhang 2024."
)
) +
theme_bw()
#> Warning in scale_y_log10(): log-10 transformation introduced infinite values.
#> log-10 transformation introduced infinite values.
#> log-10 transformation introduced infinite values.
Terminal half-life and bioavailability contrasts
The Discussion reports a terminal half-life of 35.3 days. The closed form of the two-compartment terminal rate constant from the Table 3 typical values reproduces it. Because the model is linear, typical-value exposure scales exactly with F, so the grade 1 and grade 2 AUC ratios must equal the reported relative bioavailabilities exp(-1.80) = 0.165 and exp(-3.08) = 0.0460.
kel <- 3.71 / 473
k12 <- 18.2 / 473
k21 <- 18.2 / 3434
s <- kel + k12 + k21
beta <- (s - sqrt(s^2 - 4 * kel * k21)) / 2
t_half_days <- log(2) / beta / 24
t_half_days
#> [1] 35.29555
auc_typical <- sim_typical |>
filter(time <= 120) |>
group_by(grade) |>
summarise(auc = sum(diff(time) * (head(Cc, -1) + tail(Cc, -1)) / 2)) |>
mutate(ratio_to_grade0 = auc / auc[grade == "Grade 0"])
auc_typical
#> # A tibble: 3 × 3
#> grade auc ratio_to_grade0
#> <fct> <dbl> <dbl>
#> 1 Grade 0 32.9 1
#> 2 Grade 1 5.44 0.165
#> 3 Grade 2 1.51 0.0460
stopifnot(
abs(t_half_days / 35.3 - 1) < 0.01,
# Same parameters on both sides of the ratio: pure numerical error.
abs(auc_typical$ratio_to_grade0[2] / exp(-1.80) - 1) < 1e-4,
abs(auc_typical$ratio_to_grade0[3] / exp(-3.08) - 1) < 1e-4
)PKNCA validation against Table S2
Table S2 reports dose-normalized NCA (Cmax and AUC per mg of the single dose) for day 1 (0-24 h) and day 5 (96-120 h) by overall maximum diarrhea grade, as arithmetic means. The simulated NCA uses only the Figure 1b sampling times listed above, so it carries the same sparse-sampling character as the observed NCA.
conc_nca <- sim |>
filter(time %in% sample_times, !is.na(Cc)) |>
mutate(Cc_dn = Cc_ng / dose_mg) |> # ng/mL per mg
select(id, grade, time, Cc_dn)
dose_nca <- events |>
filter(evid == 1) |>
distinct(id, grade, time) |>
mutate(amt = 1)
o_conc <- PKNCA::PKNCAconc(conc_nca, Cc_dn ~ time | grade + id)
o_dose <- PKNCA::PKNCAdose(dose_nca, amt ~ time | grade + id)
intervals <- data.frame(
start = c(0, 96), end = c(24, 120),
cmax = TRUE, tmax = TRUE, auclast = TRUE
)
nca_res <- PKNCA::pk.nca(PKNCA::PKNCAdata(o_conc, o_dose, intervals = intervals))
# Table S2 reports arithmetic means, so the simulated summary is the mean too
# (ncaComparisonTable() would otherwise pool by median). PKNCA reports Tmax
# relative to the interval start; Table S2 reports it from the first dose.
sim_mean <- as.data.frame(nca_res$result) |>
filter(PPTESTCD %in% c("cmax", "tmax", "auclast")) |>
mutate(
PPORRES = ifelse(PPTESTCD == "tmax", PPORRES + start, PPORRES),
group = paste0(grade, ", day ", ifelse(start == 0, 1, 5))
) |>
group_by(group, PPTESTCD) |>
summarise(PPORRES = mean(PPORRES), .groups = "drop")
table_s2 <- tibble(
group = paste0(rep(c("Grade 0", "Grade 1", "Grade 2"), each = 2), ", day ", c(1, 5)),
cmax = c(3.99, 10.8, 0.755, 1.58, 0.0828, 0.472),
tmax = c(15.0, 103, 22.1, 102, 12.1, 98.9),
auclast = c(60.1, 195.7, 10.8, 32.6, 1.24, 10.5)
)
cmp <- nlmixr2lib::ncaComparisonTable(
sim_mean, table_s2,
by = "group",
units = c(cmax = "ng/mL/mg", tmax = "h", auclast = "ng*h/mL/mg")
)
cmp |>
dplyr::rename("Grade and study day" = group) |>
knitr::kable(caption = paste(
"Simulated arithmetic means (200 virtual participants per grade) against",
"Table S2 (observed means; n = 14, 8 and 1 for grades 0, 1 and 2).",
"AUC is AUC0-24 on day 1 and AUC96-120 on day 5; Tmax is from the first dose."
))| NCA parameter | Grade and study day | Reference | Simulated | % diff |
|---|---|---|---|---|
| Cmax (ng/mL/mg) | Grade 0, day 1 | 3.99 | 3.68 | -7.8% |
| Cmax (ng/mL/mg) | Grade 0, day 5 | 10.8 | 8.61 | -20.2%* |
| Cmax (ng/mL/mg) | Grade 1, day 1 | 0.755 | 0.695 | -8.0% |
| Cmax (ng/mL/mg) | Grade 1, day 5 | 1.58 | 1.47 | -6.8% |
| Cmax (ng/mL/mg) | Grade 2, day 1 | 0.0828 | 0.17 | +104.8%* |
| Cmax (ng/mL/mg) | Grade 2, day 5 | 0.472 | 0.375 | -20.6%* |
| Tmax (h) | Grade 0, day 1 | 15 | 22.5 | +50.1%* |
| Tmax (h) | Grade 0, day 5 | 103 | 106 | +3.4% |
| Tmax (h) | Grade 1, day 1 | 22.1 | 23.3 | +5.6% |
| Tmax (h) | Grade 1, day 5 | 102 | 107 | +4.6% |
| Tmax (h) | Grade 2, day 1 | 12.1 | 22.6 | +86.5%* |
| Tmax (h) | Grade 2, day 5 | 98.9 | 106 | +7.3% |
| AUClast (ng*h/mL/mg) | Grade 0, day 1 | 60.1 | 59.5 | -1.0% |
| AUClast (ng*h/mL/mg) | Grade 0, day 5 | 196 | 192 | -1.7% |
| AUClast (ng*h/mL/mg) | Grade 1, day 1 | 10.8 | 11.1 | +2.4% |
| AUClast (ng*h/mL/mg) | Grade 1, day 5 | 32.6 | 32.9 | +0.8% |
| AUClast (ng*h/mL/mg) | Grade 2, day 1 | 1.24 | 2.73 | +120.3%* |
| AUClast (ng*h/mL/mg) | Grade 2, day 5 | 10.5 | 8.4 | -20.0% |
attr(cmp, "footnote")
#> [1] "* differs from reference by more than ±20%."
chk <- sim_mean |>
inner_join(
tidyr::pivot_longer(table_s2, -group, names_to = "PPTESTCD", values_to = "ref"),
by = c("group", "PPTESTCD")
) |>
# Grade 2 is a single participant; Tmax is driven by the sparse sample times.
filter(!grepl("Grade 2", group), PPTESTCD %in% c("cmax", "auclast")) |>
mutate(pct_diff = 100 * (PPORRES / ref - 1))
chk
#> # A tibble: 8 × 5
#> group PPTESTCD PPORRES ref pct_diff
#> <chr> <chr> <dbl> <dbl> <dbl>
#> 1 Grade 0, day 1 auclast 59.5 60.1 -1.04
#> 2 Grade 0, day 1 cmax 3.68 3.99 -7.80
#> 3 Grade 0, day 5 auclast 192. 196. -1.69
#> 4 Grade 0, day 5 cmax 8.61 10.8 -20.2
#> 5 Grade 1, day 1 auclast 11.1 10.8 2.39
#> 6 Grade 1, day 1 cmax 0.695 0.755 -7.97
#> 7 Grade 1, day 5 auclast 32.9 32.6 0.830
#> 8 Grade 1, day 5 cmax 1.47 1.58 -6.83
stopifnot(
# Centre: a mis-transcribed clearance, volume or grade effect on F moves
# every exposure metric by tens of percent or more.
abs(median(chk$pct_diff)) < 20,
# Envelope: the Table S2 means come from 8-14 participants with 47-71% CVs.
max(abs(chk$pct_diff)) < 40
)The day-1 and day-5 exposures for grades 0 and 1 agree with Table S2; the AUCs are within a few percent. Day-1 Tmax can only take the sampled values (the last two day-1 samples are at 13 and 24 h), and with three doses a day most virtual participants peak at the 24-h sample, whereas the observed grade 0 mean of 15 h shows that many observed participants peaked at 13 h. The grade 2 rows compare a single observed participant with the model’s grade-2 population mean and are expected to differ: that participant’s individual random effects are not known, and the model’s grade 2 effect was estimated from that participant’s whole profile rather than from these two summary numbers.
Assumptions and deviations
-
Proportional residual error not reported. Equation
1 is a combined proportional and additive model, but Table 3 prints a
single sigma (0.00268). In a Phoenix additive-plus-multiplicative model
with a single reported sigma this is the additive SD, here in mg/L (2.68
ng/mL; the assay range was 1-1000 ng/mL). The proportional SD is not
given anywhere in the paper or supplement and is fixed to 0
(
propSd = fixed(0)), so simulations that include residual error under-represent the variability at high concentrations. - IIV variances. Table 3 reports IIV and IOV as %CV. The variances use omega^2 = log(1 + CV^2), the exact log-normal relationship; the paper does not state which conversion its CVs used.
-
Inter-occasion variability on F. The paper defines
eight occasions, one per PK visit (days 1-6 and two follow-up visits). F
only acts on doses, which all fall on days 1-5, so only occasions 1-5
can change a prediction; these carry a shared variance
(
etaiov_fdepot_1to_5). Any otherOCCvalue switches the occasion effect off.OCCmust be set on the dose records. -
Overall maximum diarrhea grade is a subject-level,
time-fixed summary of all stool assessments during the study (before
each dose on days 1-5 and once on day 6). It is encoded with the level
indicators
DIARRHEA_MAX_GRADE_1andDIARRHEA_MAX_GRADE_2(reference: grade 0). Because the grade is known only after the dosing period ends, the model describes the association reported by the paper and is not a prospective dose-adjustment rule. The grade 2 effect rests on a single participant. - Day-6 sample time. Figure 1b does not show the day-6 sample time; the virtual sampling places it at 120 h (the morning of day 6) to close the day-5 96-120 h AUC interval used by Table S2.
- Dose. The virtual cohort uses 50 mg per dose throughout (20 of the 23 participants). The model is linear, so dose-normalized results do not depend on this choice.
- NCA on individual predictions. The simulated NCA uses the model prediction without residual error; with an additive SD of 2.68 ng/mL the residual error would add substantial noise to the grade 2 concentrations.
-
Screened covariates not retained (HIV viral load,
CD4 count, age and body weight) are documented in
covariatesDataExcluded; the paper reports no coefficient for them in the final model.